The FDA recommends that patients who take Tamiflu (Roche) to treat influenza be closely monitored for signs of abnormal behavior. Tamiflu is indicated for patients one year of age and older with uncomplicated acute illness caused by influenza who have shown symptoms for no more than two days.
More than 100 new cases of delirium, hallucinations, and other unusual psychiatric behavior have been reported in children who were given the drug. Most of these patients were children in Japan, where Tamiflu canadian usage is the highest in the world. The new cases of behavioral changes occurred between August 2005 and July 2006.
Health officials have been sensitive about taking any action that might dissuade people from taking Tamiflu, because the drug may be important in an outbreak of bird flu.
The drug does not prevent influenza, but it can reduce the length and severity of associated symptoms.